Company intelligence / Profile preview
eFFECTOR Therapeutics
San Diego or formerly Solana Beach, California, United Stateseffector.com ↗
- Ownership
- Public · EFTR
- Employees
- ~14
- Development stage
- Phase 2
01
Overview
The company’s lead candidate tomivosertib, an MNK inhibitor, was evaluated in a randomized Phase 2b trial in combination with pembrolizumab for metastatic NSCLC. Zotatifin, an eIF4A inhibitor, was in a Phase 1/2 trial for certain solid tumors. A third program targeted eIF4E inhibitors. The company ceased operations as of early/mid–2025 and clinical results are not being further advanced.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborated with Merck for KEYTRUDA combination studiesacademic collaborations not specified but referenced investigator-sponsored trials and research center partnerships.
04
Financials
- Market cap
- $941
- Total revenue
- $0
- Enterprise value
- $-5.1M
Beyond the preview
Go deeper on eFFECTOR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eFFECTOR Therapeutics.